A randomized, multi-center.double-blinded, placebo-controlled phase 3 study of Nivolumab and Ipilimimab, Nivolumab Monotherapy, or placebo in combination with trans-arterial Chemoembolization (TACE) in patients with Intermediate-stage Hepatocellular Carcinoma (HCC)
Ficha Técnica
Investigador Principal
JOSE LUIS MONTERO ALVAREZ
Promotor
BRISTOL-MYERS SQUIBB INTERNATIONAL CORPORATION (BMSIC)